G. Beatch

发表

Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.

A. Camm, E. Toft, D. Wyse, 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

RSD1000: a novel antiarrhythmic agent with increased potency under acidic and high-potassium conditions.

A. Zolotoy, G. Beatch, J. Mclarnon, 1999, The Journal of pharmacology and experimental therapeutics.

TMS as a pharmacodynamic indicator of cortical activity of a novel anti‐epileptic drug, XEN1101

E. Abela, M. Richardson, I. Premoli, 2019, Annals of clinical and translational neurology.

Magnesium shifts voltage dependence of activation of delayed rectifier I(K) in guinea pig ventricular myocytes.

G. Beatch, B. Williams, 1997, The American journal of physiology.

Rate-dependent effects of sematilide on ventricular monophasic action potential duration and delayed rectifier K+ current in rabbits.

D. Davis, G. Beatch, S. Laganière, 1996, Journal of cardiovascular pharmacology.

Ventricular arrhythmias following coronary artery occlusion in the streptozotocin diabetic rat.

J. McNeill, G. Beatch, 1988, Canadian journal of physiology and pharmacology.

Better antiarrhythmics? Development of antiarrhythmic drugs selective for ischaemia‐dependent arrhythmias

D. Fedida, T. Barrett, M. Pugsley, 1997 .

Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.

A. Camm, C. Torp-Pedersen, G. Beatch, 2013, International journal of cardiology.

Ventricular fibrillation, an uncontrolled arrhythmia seeking new targets

T. Barrett, A. Zolotoy, Bertrand Plouvier, 2002 .

Antiarrhythmic actions of tedisamil: Studies in rats and primates

G. Beatch, M. Walker, G. Adaikan, 1992, Cardiovascular Drugs and Therapy.

Antiarrhythmic properties of tedisamil (KC8857), a putative transient outward K+ current blocker

B. MacLeod, G. Beatch, M. Walker, 1991, British journal of pharmacology.

Pharmacological and toxicological activity of RSD921, a novel sodium channel blocker.

A. L. Goldin, B. MacLeod, D. Saint, 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues

C. Regan, G. Gleim, J. Lynch, 2013, Journal of cardiovascular pharmacology.

The Mechanism of Atrial Antiarrhythmic Action of RSD1235

D. Fedida, Bertrand Plouvier, G. Beatch, 2005, Journal of cardiovascular electrophysiology.

A Randomized, Placebo-Controlled Study of Vernakalant (Oral) for the Prevention of Atrial Fibrillation Recurrence After Cardioversion

C. Torp-Pedersen, G. Beatch, G. Dickinson, 2011, Circulation. Arrhythmia and electrophysiology.

RSD931, a novel anti‐tussive agent acting on airway sensory nerves

C. Page, G. Beatch, J. Adcock, 2003, British journal of pharmacology.

Mexiletine's antifibrillatory actions are limited by the occurrence of convulsions in conscious animals.

G. Beatch, M. Walker, K. Mcerlane, 1992, European journal of pharmacology.

Mechanisms underlying the antiarrhythmic properties of β‐adrenoceptor blockade against ischaemia‐induced arrhythmias in acutely prepared rats

G. Beatch, M. Walker, S. Abraham, 1989, British journal of pharmacology.

Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia–Pacific Region: A Phase 3 Randomized Controlled Trial

K. Bhirangi, S. Juul-Moller, G. Beatch, 2016, Journal of cardiovascular pharmacology.

Spontaneous and TMS-related EEG changes as new biomarkers to measure anti-epileptic drug effects

M. Richardson, I. Premoli, A. Biondi, 2022, Scientific Reports.

Tissue distribution of mexiletine enantiomers in rats.

G. Beatch, M. Walker, K. Mcerlane, 1991, Xenobiotica; the fate of foreign compounds in biological systems.

Kinetics of rate‐dependent shortening of action potential duration in guinea‐pig ventricle; effects of IK1 and IKr blockade

G. Beatch, Beatrice A Williams, David R Dickenson, 1999, British journal of pharmacology.

Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial

G. Beatch, B. Mangal, 2016, BMC Cardiovascular Disorders.

A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation.

A. Capucci, I. V. Van Gelder, S. Hohnloser, 2011, Journal of the American College of Cardiology.

A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation.

I. Stiell, B. Rowe, J. Lee, 2004, Journal of the American College of Cardiology.

The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans

V. Korley, P. Dorian, G. Beatch, 2007, Journal of cardiovascular pharmacology.

Class III antiarrhythmic effects of LY-190147 on defibrillation threshold.

A. Tang, G. Beatch, D. Dickenson, 1996, Journal of cardiovascular pharmacology.

Effects of Optical Enantiomers CK‐4000(S) and CK 4001(R) on Defibrillation and Enhancement of Shock‐ Induced Extension of Action Potential Duration

A. Tang, G. Beatch, D. Dickenson, 1995, Journal of cardiovascular electrophysiology.

P Cardiac Rhythm Disturbances Randomized , Controlled Trial of SD 1235 , a Novel AntiArrhythmic Agent , n the Treatment of Recent Onset Atrial Fibrillation

I. Stiell, B. Rowe, J. Lee, 2016 .

RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents.

D. Fedida, G. Beatch, David Fedida, 2006, Cardiovascular research.

Pharmacokinetics of Novel Atrial‐Selective Antiarrhythmic Agent Vernakalant Hydrochloride Injection (RSD1235): Influence of CYP2D6 Expression and Other Factors

J. Keirns, L. Clohs, G. Beatch, 2009, Journal of clinical pharmacology.

Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues

C. Regan, G. Gleim, J. Lynch, 2013, Journal of cardiovascular pharmacology.